Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
Annals of the Rheumatic Diseases, ISSN: 0003-4967, Vol: 69, Issue: 11, Page: 1913-1919
2010
- 170Citations
- 172Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations170
- Citation Indexes165
- 165
- CrossRef146
- Clinical Citations4
- PubMed Guidelines4
- Policy Citations1
- Policy Citation1
- Captures172
- Readers172
- 170
- Mentions2
- News Mentions2
- News2
Most Recent News
Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis; CORRA
STUDY INFORMATION OFFICIAL TITLE: Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo
Review Description
To develop recommendations on monitoring for adverse events (AEs) of low-dose glucocorticoid (GC) therapy (≤7.5 mg prednisone or equivalent daily) in clinical trials and daily practice. Literature was searched for articles containing information on incidence and monitoring of GC-related AEs using PubMed, EMBASE and Cochrane databases. Second, the authors searched for broad accepted guidelines on the monitoring of certain AEs (eg, WHO guidelines on screening for diabetes). Available data were summarised and discussed among experts (rheumatologists and patients) of the EULAR Task Force to decide which potential AEs should be monitored, how and at which interval. Data on monitoring proved to be scarce; most articles were focused on therapeutic effects of GCs, not on occurrence and monitoring of AEs. Most recommendations had to be based on consensus. Those for clinical trials aimed at getting insights into incidence, prevalence and clinical relevance of AEs to create a comprehensive and valid AE-profile of GC therapy. The set of AEs to monitor is therefore more extensive, and often consists of assessments at baseline and at end of trials. Recommendations for daily practice are meant to protect patients from real dangers, which can be prevented or treated. Standard care monitoring needs NOT be extended for patients on low-dose GC therapy, except for osteoporosis (follow national guidelines), and baseline assessments of ankle edema, fasting blood glucose and risk factors for glaucoma. Given the incompleteness of literature data, consensus-based recommendations on monitoring for GC-related AEs were created, separately for daily practice and clinical trials.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0003496724147826; http://dx.doi.org/10.1136/ard.2009.124958; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955455011&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/20693273; https://linkinghub.elsevier.com/retrieve/pii/S0003496724147826; https://dx.doi.org/10.1136/ard.2009.124958; https://ard.bmj.com/content/69/11/1913; http://ard.bmj.com/content/69/11/1913; https://ard.bmj.com/content/69/11/1913.abstract; https://ard.bmj.com/content/69/11/1913.full.pdf; http://ard.bmj.com/content/69/11/1913.long; http://ard.bmj.com/cgi/doi/10.1136/ard.2009.124958; https://ard.bmj.com/content/annrheumdis/69/11/1913.full.pdf; http://ard.bmj.com/lookup/doi/10.1136/ard.2009.124958; http://europepmc.org/abstract/med/20693273
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know